CClinicalTrials.gg
CompletedNCT04468386Updated Nov 24, 2021

Specimen Collection Study Protocol

An observational study in Focus in on Collecting Paired Specimens for Matrix Equivalency, sponsored by Biomerica. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Biomerica · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
47
Ages
21 Years and older
Sex
All
01

Study summary

The specimens collected will be used to evaluate matrix equivalency in an immunoassay in development for the detection of IgG or IgA or IgM antibodies to SARS - CoV2 in human serum. These reagents are for in vitro diagnostic use only.

Read the detailed description

The objective of this study is to acquire paired serum, plasma and whole blood collected on a collection card from subjects with no known history of COVID-19 infection. The specimens will be collected at Biomerica in Irvine CA for specimen collection, banking, and matrix equivalency studies for projects in development at Biomerica for detection to IgG or IgA or IgM antibodies to Sars-CoV2 antibodies. Subject will also be asked to self-collect a nasal swab for COVID-19 PCR

02

Conditions studied

  • Focus in on Collecting Paired Specimens for Matrix Equivalency
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of subjects identified as meeting the inclusion/exclusion criteria from Biomerica employees and/or friends and family of Biomerica's employees. There will be no outside advertising or recruiting. All subjects must be willing to sign the informed consent and undergo the venipuncture and finger stick blood collection process and perform the nasal swab collection.

Inclusion criteria

  • Aged 21 and older
  • Able to read, speak, and understand English
  • Must weigh a minimum of 110 pounds
  • Willing and able to donate 20 mLs of whole blood via venipuncture. [approximately ˂ 2 tablespoons]
  • Willing and able to donate 0.040 mLs of whole blood via fingerstick
  • Willing and able to sign the informed consent (self or authorized representative)
  • Willing and able to self-collect a nasal swab per the provided instruction shee

Exclusion criteria

Exclusion Criteria:

  • Aged less than 21 years old
  • Unable to provide consent.
  • Unable to donate blood via venipuncture and fingerstick.
  • Unable to self-collect a nasal swab
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
47 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
05

What researchers measure

Primary outcomes

  1. Matrix Equivalency

    This study is designed to collect specimens to support specimen matrix equivalency in an in vitro diagnostic assay for the detection of COVID-19 antibodies. Additionally, specimens collected via finger stick will be used to validate a whole blood collection card that could be used in the field by trained professionals and sent back to central reference laboratories for testing.

    Time frame: 1 day

06

Study locations

1 site
  • Biomerica, Inc.
    Irvine, California 92614, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04468386
Lead sponsor
Biomerica
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Jul 7, 2020
Primary completion
May 30, 2021
Completion
May 30, 2021
Last update
Nov 24, 2021

Study contacts

Elisabeth Laderman, Ph.D.
principal investigator · Biomerica, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion